Raloxifene Reduces IGF-I Levels in Postmenopausal Women with Breast Cancer
Author Information
Author(s): da Silva Benedito B, Moita Daniel S, Pires Cleicilene G, Sousa-Junior Edílson C, dos Santos Alesse R, Lopes-Costa Pedro V
Primary Institution: Federal University of Piauí
Hypothesis
Does raloxifene treatment reduce serum IGF-I levels in postmenopausal women with breast cancer?
Conclusion
Raloxifene significantly reduced serum IGF-I levels in postmenopausal women with breast cancer.
Supporting Evidence
- Mean serum IGF-I levels decreased from 143.7 ng/ml before treatment to 94.8 ng/ml after treatment.
- The reduction in serum IGF-I levels was statistically significant.
- Raloxifene was administered for 28 days prior to surgery.
Takeaway
This study found that taking raloxifene for 28 days lowers a certain hormone level in women after menopause who have breast cancer.
Methodology
Twenty-two postmenopausal women with operable, stage I or II, estrogen receptor-positive breast cancer received 60 mg of raloxifene for 28 days, and serum IGF-I levels were measured before and after treatment.
Potential Biases
Potential bias due to lack of randomization and control group.
Limitations
The study was not placebo-controlled and lacked randomization.
Participant Demographics
Participants were postmenopausal women aged 47 to 87 years, with a mean age of 63 years.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website